Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine Versus Levothyroxine
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CONTEXT: Levothyroxine (L-T(4)) therapy is based on the assumption that the conversion of T(4) into T(3) provides adequate amounts of active hormone at target tissues. However, in rodents, L-T(4) alone does not restore a euthyroid state in all tissues. Previous combination L-T(4)/liothyronine (L-T(3)) therapy trials focused on quality-of-life endpoints, and limited information is available on the effects on other measures of thyroid hormone action. OBJECTIVE: Our objective was to evaluate the efficacy of thyroid hormone replacement with L-T(4) or L-T(3) at doses producing equivalent normalization of TSH. PARTICIPANTS, DESIGN, AND SETTING: Fourteen hypothyroid patients participated in this randomized, double-blind, crossover intervention at the National Institutes of Health Clinical Center. INTERVENTIONS: L-T(3) or L-T(4) were administered thrice daily to achieve a target TSH from 0.5-1.5 mU/liter. Volunteers were studied as inpatients after 6 wk on a stable dose and at the target TSH. MAIN OUTCOME MEASURES: Serum thyroid hormones, lipid parameters, and indices of glucose metabolism were evaluated. RESULTS: No difference was observed in TSH between L-T(3) and L-T(4) treatments. L-T(3) resulted in significant weight loss [L-T(4), 70.6 ± 12.5, vs. L-T(3), 68.5 ± 11.9 kg (P = 0.009)] and in a 10.9 ± 10.0% decrease in total cholesterol (P = 0.002), 13.3 ± 12.1% decrease in low-density lipoprotein-cholesterol (P = 0.002), and an 18.3 ± 28.6% decrease in apolipoprotein B (P = 0.018). No significant differences were observed in high-density lipoprotein-cholesterol, heart rate, blood pressure, exercise tolerance, or insulin sensitivity. CONCLUSIONS: The substitution of L-T(3) for L-T(4) at equivalent doses (relative to the pituitary) reduced body weight and resulted in greater thyroid hormone action on the lipid metabolism, without detected differences in cardiovascular function or insulin sensitivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LT3 monotherapy administered three times daily produces stable TSH levels with continued fluctuations in T3 levels, such that they reach the upper end of the normal range with each of the three dose administrations (75,76).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Moreover, as judged by the length of time that it took over the course of the study to reach and maintain the goal TSH, it is too frequent a dosing regimen for participants to easily adhere to.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Sex hormone-binding globulin was also significantly increased, reflecting the hepatic impact of LT3 (75).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Treatment with LT3 alone was associated with lowered total and low-density lipoprotein cholesterol and decreased body weight, presumably reflecting the action of T3 on lipid and energy metabolism.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“A crossover design is appealing because of the increase in statistical power due to the ability to perform paired analyses, as has been performed in prior studies (23,46,50,52,58,59,75,76,107).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedüs, L., Vitti, P., Gharib, H., Papini, E., Paschke, R., et al. (2010) · Endocrine Practice · doi:10.4158/10024.gl · Cited by 1,088
Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling1
Gereben, B., Zavacki, A. M., Ribich, S., Kim, B. W., Huang, S. A., Simonides, W. S., Zeöld, A., & Bianco, A. C. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0019 · Cited by 891 · cited 2×
“This is not surprising because type-2 deiodinase (30) is particularly active in the thyrotroph, and it is thought to play a major role in the hypothalamuspituitary-thyroid axis (27, 31).”
BackgroundThe modification of diet in renal disease study group
Beck, G. J., Berg, R. L., Coggins, C. H., Gassman, J. J., Hunsicker, L. G., Schluchter, M. D., & Williams, G. W. (1991) · Controlled Clinical Trials · doi:10.1016/0197-2456(91)90069-x · Cited by 818
Gharib, H., Papini, E., Valcavi, R., Baskin, H. J., Crescenzi, A., Dottorini, M. E., Duick, D. S., Guglielmi, R., Hamilton, C. R., Zeiger, M. A., et al. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.63 · Cited by 681
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“tion within the normal laboratory reference limits (12).”
BackgroundBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482
Treatment Guidelines for Patients With Hyperthyroidism and Hypothyroidism
Singer, P. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520340064038 · Cited by 427
Bianco, A. C. (2002) · Endocrine Reviews · doi:10.1210/er.23.1.38 · Cited by 423
Hennemann, G., Docter, R., Friesema, E. C. H., de Jong, M., Krenning, E. P., & Visser, T. J. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0435 · Cited by 394
Thyroid Hormone as a Determinant of Energy Expenditure and the Basal Metabolic Rate
Kim, B. (2008) · Thyroid · doi:10.1089/thy.2007.0266 · Cited by 382
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Levothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324
Harington, C. R., & Barger, G. (1927) · Biochemical Journal · doi:10.1042/bj0210169 · Cited by 319 · cited 1×
“Since 1891, hypothyroidism has been treated with replacement therapy, initially using desiccated thyroid gland (3), and since the 1930s with levothyroxine (L-T4) (4), the sodium salt of the natural thyroid hormone (TH) tetraiodothyronine (T4).”
BackgroundEscobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Molecular biological and biochemical characterization of the human type 2 selenodeiodinase.
Salvatore, D., Bartha, T., Harney, J. W., & Larsen, P. R. (1996) · Endocrinology · doi:10.1210/endo.137.8.8754756 · Cited by 284
Escobar-Morreale, H. F., del Rey, F. E., Obregón, M. J., & de Escobar, G. M. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641203 · Cited by 261 · cited 4×
“J Clin Endocrinol Metab, November 2011, 96(11):3466–3474 jcem.”
BackgroundInfluentialSINGER, P. A. (1995) · JAMA · doi:10.1001/jama.273.10.808 · Cited by 235
Murray, G. R. (1891) · BMJ · doi:10.1136/bmj.2.1606.796 · Cited by 232
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216 · cited 1×
“with L-T4 is the current standard of care (5–8), based on the assumption that conversion of inactive T4 into hormonally active T3 provides an adequate amount of TH at the target end-organs (9).”
BackgroundWalsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Clyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195 · cited 8×
“After equilibration, glucose disposal rate was calculated over a 20-min period while serum glucose was maintained within the range 95–105 mg/dl. Quality of life assessment A psychological well-being metric (SF-36) and the hypothyroid-specific health-related QOL questionnaire were administered on study d 2.”
BackgroundInfluentialPilo, A., Iervasi, G., Vitek, F., Ferdeghini, M., Cazzuola, F., & Bianchi, R. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.4.e715 · Cited by 185
Appelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182
Indirect calorimetry: methodology, instruments and clinical application
da Rocha, E. E. M., Alves, V. G. F., & da Fonseca, R. B. V. (2006) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/01.mco.0000222107.15548.f5 · Cited by 177
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175 · cited 1×
“A single study allowed dose titration, but the data reported were limited to QOL and psychological endpoints (21).”
MethodSiegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152
Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1672 · Cited by 136
Modeling weight-loss maintenance to help prevent body weight regain
Hall, K. D., & Jordan, P. N. (2008) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26333 · Cited by 122
Hennemann, G. (2001) · Endocrine Reviews · doi:10.1210/er.22.4.451 · Cited by 122
Christoffolete, M. A., Ribeiro, R., Singru, P., Fekete, C., da Silva, W. S., Gordon, D. F., Huang, S. A., Crescenzi, A., Harney, J. W., Ridgway, E. C., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1300 · Cited by 118
Slawik, M., Klawitter, B., Meiser, E., Schories, M., Zwermann, O., Borm, K., Peper, M., Lubrich, B., Hug, M. J., Nauck, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0297 · Cited by 113
Bunevicius, R., Jakubonien, N., Jurkevicius, R., Cernicat, J., Lašas, L., & Prange, A. J. (2002) · Endocrine · doi:10.1385/endo:18:2:129 · Cited by 111
Celi, F. S., Zemskova, M., Linderman, J. D., Babar, N. I., Skarulis, M. C., Csako, G., Wesley, R., Costello, R., Penzak, S. R., & Pucino, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03700.x · Cited by 65 · cited 3×
“Drug dosage, serum TH levels, and TRH-stimulation test of the first 10 patients who completed the study have been reported elsewhere (25).”
BackgroundSelf-citationGouveia, C. H. A., Christoffolete, M. A., Zaitune, C. R., Dora, J. M., Harney, J. W., Maia, A. L., & Bianco, A. C. (2005) · Endocrinology · doi:10.1210/en.2004-1043 · Cited by 63
Fasting and postabsorptive hepatic glucose and insulin metabolism in hyperthyroidism
Raboudi, N., Arem, R., Jones, R. H., Chap, Z., Peña, J. R. A., Chou, J., & Field, J. B. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.256.1.e159 · Cited by 40
Blohmke, M. (1957) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1116902 · Cited by 24
Emerging drugs for hyperlipidemia
Paras, C., Hussain, M. M., & Rosenson, R. S. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.481282 · Cited by 20
Levothyroxine Therapy in Patients with Thyroid Disease
SJ, M., GA, B., & PR., L. (1994) · The Endocrinologist · doi:10.1097/00019616-199403000-00019 · Cited by 17
Mazzaferri, E. L. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70611-4 · Cited by 12
Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3′-Triiodothyronine
Blanchard, K. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031971 · Cited by 10
Cited by
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“A potential role for L-triiodothyronine monotherapy in lieu of L-thyroxine monotherapy was recently raised by a small randomized, double-blind crossover intervention study done comparing L-triiodothyronine monotherapy with L-thyroxine monotherapy in patients with hypothyroidism (298).”
Mechanisms of thyroid hormone action
Brent, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60047 · Cited by 1,244
“Interestingly, providing hypothyroid human subjects with only T3 rather than T4, but keeping their TSH in the normal reference range, also results in reduced LDL cholesterol and slight weight loss (120).”
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Metadata
- Authors
- Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., & Pucino, F.
- Affiliations
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- Corresponding author
- Celi, Francesco S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-11
- Volume
- 96
- Issue
- 11
- Pages
- 3466-3474
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3205882
- OpenAlex
- W2057697685
- Cited by
- 125
- References
- 48
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 8 · 2015: 3 · 2014: 13 · 2013: 11 · 2012: 13
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01-DK047057-02, Z01DK047057)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- liothyronine, levothyroxine, hypothyroidism, thyroid hormone replacement, lipid metabolism, cholesterol, apolipoprotein B, weight loss, insulin sensitivity, thyroid-stimulating hormone, cardiovascular function, exercise tolerance, glucose metabolism, thyroid hormone action, crossover trial, apolipoprotein A-I, apolipoprotein C
- MeSH terms
- Adult, Aged, Apolipoproteins B, Body Composition, Cholesterol, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypothyroidism, Male, Middle Aged, Quality of Life, Thyroid Hormones, Thyroxine, Triiodothyronine, Bone Density, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.